View on market: Stay Cautious, be with quality business:
Asian stocks fell as investors weighed uncertainties about the omicron variant and looked to U.S. inflation data amid the Federal Reserve’s hawkish tilt. Treasuries pared some of Friday’s rally. Equity benchmarks dropped in Japan, South Korea and Australia. S&P 500 futures rose, while Nasdaq 100 contracts slipped. U.S. stocks extended a weekly slide Friday after a mixed U.S. jobs report fanned volatility. The Singapore-traded SGX Nifty, an early indicator of India’s Nifty 50 Index’s performance, was little changed at 17,268, as of 8:05 a.m.
Economic Calendar:
- INR: Interest Rate Decision on 8th December, 2021.
- INR: FX Reserves, USD on 10th December, 2021.
- USD: JOLTSs Job Opening (Oct) on 8th December, 2021.
- USD: Crude Oil Inventories on 8th December, 2021.
Brokerage Radar:
JEFFERIES ON SIEMENS: Maintain buy at the price of Rs 2192 for the target price of Rs 2560. Management optimistic on central govt infra spend rising & pvt sector uptick. State spend scale-up is gradual, data centres & hospitals strong on order flow. Will benefit from margin traction as rev rises on higher decarbonisation. Lower FY22-23 EPS By 2-4% to factor Q4 margin impact of commodity/logistics costs.
CLSA ON ICICI BANK: Maintain buy at the price of Rs 717.15 for the target price of Rs 1100. Mgmt focus is shifting towards building infra for new-to-bank customers. Successfully improved granularity & quality of its earnings over the past 6-7 yrs. Bank ahead of peers in its digital initiatives & is also a new growth leader. Co remains one of their top picks in the sector.
NOMURA ON STEEL: Chinese steel pricing outlook uncertain. JSW steel’s December price cut on expected lines. Near-term demand from property market. May weaken but at a slower pace. China’s blast furnace utilisation at 75.23%, down 10 bps wow, 6th week of decline. JSW steel price cut reflects weak domestic/export demand.
International Markets:
U.S & Europe
| Particulars | 03rd Dec | Chg | Chg(%) |
| Nasdaq | 15,085.47 | -295.85 | -1.92 |
| Dow | 34,580.08 | -59.71 | -0.17 |
| FTSE | 7,122.32 | -6.89 | -0.10 |
| CAC | 6,765.52 | -30.23 | -0.44 |
| DAX | 15,169.98 | -93.13 | -0.61 |
| Dow Fut.* | 34,787.00 | 221.00 | 0.64 |
*As per 6th Dec.
Asian markets:
| Particulars | 6th Dec | Chg | Chg(%) |
| SGX Nifty | 17,268.00 | 33.00 | 0.19 |
| Nikkei | 27,862.00 | -167.57 | -0.60 |
| Straits Times | 3,132.71 | 30.78 | 0.99 |
| Hang Seng | 23,551.39 | -215.30 | -0.91 |
| Shanghai | 3,624.65 | 17.22 | 0.48 |
ADR Watch:
| Particulars | 3rdDec | Chg | Chg(%) |
| Dr Reddy | 60.52 | -1.88 | -3.01 |
| HDFC Bank | 66.27 | -0.89 | -1.33 |
| ICICI Bank | 18.48 | -0.21 | -1.12 |
| Infosys | 22.88 | -0.56 | -2.39 |
| Tata Motor | 31.45 | -0.52 | -1.63 |
| Wipro | 8.59 | -0.16 | -1.83 |
Commodities & Currency
| Particulars | Current Price | Chg(%) |
| USD/INR | 75.16 | 0.22 |
| Brent | 71.38 | 2.06 |
| Gold | 1787.50 | 0.20 |
| Silver | 22.552 | 0.32 |
FIIs & DII
| Particulars | 3rd Dec | 2nd Dec |
| FIIs | -3356.17 | -909.71 |
| DIIs | 1648.79 | 1372.65 |
News Update:
Eris Lifesciences: The company has formed a joint venture with MJ Biopharm to enter the insulin segment. The 70:30 JV (with Eris holding a 70% stake) will primarily engage in the marketing and distribution of human and analogue insulins (Glargine, Aspart, Lispro) and GLP-1 agonists (Liraglutide) among other biopharma products in India.
Tech Mahindra: The company has acquired Activus Connect for $62 million. The acquisition will bolster Tech Mahindra’s capabilities in emerging workplace solutions and strengthen end-to-end CX portfolio.
Lupin: The company has entered into a distribution and marketing agreement with Biomm SA in Brazil. Under the agreement, Biomm will distribute and market biosimilar Pegfilgrastim in Brazil.
Lloyds Metals and Energy: The mining lease granted to the company for iron ore mines over an area of 348.09 Ha. in Surjagad (Wooria Hill) in Gadchiroli district has been extended for a further period of 30 years and is now valid up till May 2, 2057.
Carborundum Universal: CUMI International, Cyprus, a wholly-owned subsidiary of the company, has entered into an agreement to acquire an existing company in Germany which will become a step-down subsidiary of CUMI. This acquisition will facilitate a base in European Union facilitating CUMI Group accessing markets in EU for its portfolio viz., abrasives, ceramics and electrominerals.
Tatva Chintan Pharma Chem: Appointed Ashok Bothra as Chief Financial Officer and Key Managerial Personnel of the company.
NMDC: Declared interim dividend of Rs 9.01 per share for the financial year 2021- 22. It has fixed December 15 as the record date for the payment of dividend.
Dr Lal PathLabs: Approved the reappointment of Arvind Lal as executive chairman and whole-time director of the company, for a period of 5 years commencing from April 1, 2022.
Persistent Systems: HDFC Asset Management Company sold 15.76 lakh equity shares, representing 2.06 percent stake, of the company through open market transactions on December 2. With this, the AMC’s shareholding falls to 5.14 percent from 7.20 percent earlier.
Krsnaa Diagnostics: Crisil Ratings has upgraded the company’s long term credit rating to CRISIL BBB+/Positive from CRISIL BBB/Positive and short term credit rating to CRISIL A2 from CRISIL A3+.
India PesticideS: CARE Ratings has reviewed the credit ratings assigned to the company’s long term and short term credit facilities to CARE A+ from CARE A with the outlook remaining stable.
Source: Moneycontrol, Livemint,, Bloomberg, Investing
Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014
Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitewealth.in with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitewealth.in
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL